Cargando…

Elevated Serum Lysophosphatidylcholine in Patients with Systemic Lupus Erythematosus Impairs Phagocytosis of Necrotic Cells In Vitro

OBJECTIVES: Impaired clearance of dying and dead cells by professional and amateur phagocytes plays a crucial role in the etiology of systemic lupus erythematosus (SLE). While dying, cells expose and release a plethora of eat-me and find-me signals to ensure their timely removal before entering the...

Descripción completa

Detalles Bibliográficos
Autores principales: Grossmayer, Gerhard E., Keppeler, Hildegard, Boeltz, Sebastian, Janko, Christina, Rech, Jürgen, Herrmann, Martin, Lauber, Kirsten, Muñoz, Luis E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5776078/
https://www.ncbi.nlm.nih.gov/pubmed/29387051
http://dx.doi.org/10.3389/fimmu.2017.01876
_version_ 1783294009625542656
author Grossmayer, Gerhard E.
Keppeler, Hildegard
Boeltz, Sebastian
Janko, Christina
Rech, Jürgen
Herrmann, Martin
Lauber, Kirsten
Muñoz, Luis E.
author_facet Grossmayer, Gerhard E.
Keppeler, Hildegard
Boeltz, Sebastian
Janko, Christina
Rech, Jürgen
Herrmann, Martin
Lauber, Kirsten
Muñoz, Luis E.
author_sort Grossmayer, Gerhard E.
collection PubMed
description OBJECTIVES: Impaired clearance of dying and dead cells by professional and amateur phagocytes plays a crucial role in the etiology of systemic lupus erythematosus (SLE). While dying, cells expose and release a plethora of eat-me and find-me signals to ensure their timely removal before entering the dangerous stage of secondary necrosis. A well-described chemoattractant for macrophages is dying cell-derived lysophosphatidylcholine (LPC). However, its implications for and/or its association with SLE disease, so far, have not been examined. In the present study, we analyzed the LPC serum concentrations of patients with SLE and rheumatoid arthritis (RA). Subsequently, we examined if and to which extent the measured serum concentrations of LPC and an LPC-rich environment can impact the phagocytosis of necrotic cells. METHODS: Sera from patients with SLE, RA, and normal healthy donors (NHD) were characterized for several parameters, including LPC concentrations. Phagocytosis of dead cells by human macrophages in the presence of SLE and NHD sera was quantified. Additionally, the impact of exogenously added, purified LPC on phagocytosis was analyzed. RESULTS: Patients with SLE had significantly increased LPC serum levels, and high serum LPC of SLE patients correlated significantly with impaired phagocytosis of dead cells in the presence of heat-inactivated serum. Phagocytosis in the presence of sera from NHD showed no correlation to LPC levels, but exogenous addition of purified LPC in the range as measured in SLE patients’ sera led to a concentration-dependent decrease. CONCLUSION: Our data show that high levels of LPC as observed in the sera of SLE patients have a negative impact on the clearance of dead cells by macrophages. Chemoattraction requires a concentration gradient. The higher the LPC concentration surrounding a dying or dead cell, the smaller the achievable gradient upon LPC release will be. Thus, it is feasible to assume that elevated LPC levels can interfere with the build-up of a local LPC gradient during cell death, and hence might play a role in the establishment and/or perpetuation of SLE disease.
format Online
Article
Text
id pubmed-5776078
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-57760782018-01-31 Elevated Serum Lysophosphatidylcholine in Patients with Systemic Lupus Erythematosus Impairs Phagocytosis of Necrotic Cells In Vitro Grossmayer, Gerhard E. Keppeler, Hildegard Boeltz, Sebastian Janko, Christina Rech, Jürgen Herrmann, Martin Lauber, Kirsten Muñoz, Luis E. Front Immunol Immunology OBJECTIVES: Impaired clearance of dying and dead cells by professional and amateur phagocytes plays a crucial role in the etiology of systemic lupus erythematosus (SLE). While dying, cells expose and release a plethora of eat-me and find-me signals to ensure their timely removal before entering the dangerous stage of secondary necrosis. A well-described chemoattractant for macrophages is dying cell-derived lysophosphatidylcholine (LPC). However, its implications for and/or its association with SLE disease, so far, have not been examined. In the present study, we analyzed the LPC serum concentrations of patients with SLE and rheumatoid arthritis (RA). Subsequently, we examined if and to which extent the measured serum concentrations of LPC and an LPC-rich environment can impact the phagocytosis of necrotic cells. METHODS: Sera from patients with SLE, RA, and normal healthy donors (NHD) were characterized for several parameters, including LPC concentrations. Phagocytosis of dead cells by human macrophages in the presence of SLE and NHD sera was quantified. Additionally, the impact of exogenously added, purified LPC on phagocytosis was analyzed. RESULTS: Patients with SLE had significantly increased LPC serum levels, and high serum LPC of SLE patients correlated significantly with impaired phagocytosis of dead cells in the presence of heat-inactivated serum. Phagocytosis in the presence of sera from NHD showed no correlation to LPC levels, but exogenous addition of purified LPC in the range as measured in SLE patients’ sera led to a concentration-dependent decrease. CONCLUSION: Our data show that high levels of LPC as observed in the sera of SLE patients have a negative impact on the clearance of dead cells by macrophages. Chemoattraction requires a concentration gradient. The higher the LPC concentration surrounding a dying or dead cell, the smaller the achievable gradient upon LPC release will be. Thus, it is feasible to assume that elevated LPC levels can interfere with the build-up of a local LPC gradient during cell death, and hence might play a role in the establishment and/or perpetuation of SLE disease. Frontiers Media S.A. 2018-01-17 /pmc/articles/PMC5776078/ /pubmed/29387051 http://dx.doi.org/10.3389/fimmu.2017.01876 Text en Copyright © 2018 Grossmayer, Keppeler, Boeltz, Janko, Rech, Herrmann, Lauber and Muñoz. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Grossmayer, Gerhard E.
Keppeler, Hildegard
Boeltz, Sebastian
Janko, Christina
Rech, Jürgen
Herrmann, Martin
Lauber, Kirsten
Muñoz, Luis E.
Elevated Serum Lysophosphatidylcholine in Patients with Systemic Lupus Erythematosus Impairs Phagocytosis of Necrotic Cells In Vitro
title Elevated Serum Lysophosphatidylcholine in Patients with Systemic Lupus Erythematosus Impairs Phagocytosis of Necrotic Cells In Vitro
title_full Elevated Serum Lysophosphatidylcholine in Patients with Systemic Lupus Erythematosus Impairs Phagocytosis of Necrotic Cells In Vitro
title_fullStr Elevated Serum Lysophosphatidylcholine in Patients with Systemic Lupus Erythematosus Impairs Phagocytosis of Necrotic Cells In Vitro
title_full_unstemmed Elevated Serum Lysophosphatidylcholine in Patients with Systemic Lupus Erythematosus Impairs Phagocytosis of Necrotic Cells In Vitro
title_short Elevated Serum Lysophosphatidylcholine in Patients with Systemic Lupus Erythematosus Impairs Phagocytosis of Necrotic Cells In Vitro
title_sort elevated serum lysophosphatidylcholine in patients with systemic lupus erythematosus impairs phagocytosis of necrotic cells in vitro
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5776078/
https://www.ncbi.nlm.nih.gov/pubmed/29387051
http://dx.doi.org/10.3389/fimmu.2017.01876
work_keys_str_mv AT grossmayergerharde elevatedserumlysophosphatidylcholineinpatientswithsystemiclupuserythematosusimpairsphagocytosisofnecroticcellsinvitro
AT keppelerhildegard elevatedserumlysophosphatidylcholineinpatientswithsystemiclupuserythematosusimpairsphagocytosisofnecroticcellsinvitro
AT boeltzsebastian elevatedserumlysophosphatidylcholineinpatientswithsystemiclupuserythematosusimpairsphagocytosisofnecroticcellsinvitro
AT jankochristina elevatedserumlysophosphatidylcholineinpatientswithsystemiclupuserythematosusimpairsphagocytosisofnecroticcellsinvitro
AT rechjurgen elevatedserumlysophosphatidylcholineinpatientswithsystemiclupuserythematosusimpairsphagocytosisofnecroticcellsinvitro
AT herrmannmartin elevatedserumlysophosphatidylcholineinpatientswithsystemiclupuserythematosusimpairsphagocytosisofnecroticcellsinvitro
AT lauberkirsten elevatedserumlysophosphatidylcholineinpatientswithsystemiclupuserythematosusimpairsphagocytosisofnecroticcellsinvitro
AT munozluise elevatedserumlysophosphatidylcholineinpatientswithsystemiclupuserythematosusimpairsphagocytosisofnecroticcellsinvitro